BEAT-MRT Base editing against cancer – a gene correction strategy for rhabdoid tumours
- Coordinator
- Prinses Maxima Centrum Voor Kinderoncologie BV, Netherlands
- Runs
- 1 November 2026 to 30 April 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101333636
What the project is doing
In the project's own words, from its summary on CORDIS.
Malignant rhabdoid tumours (MRTs) are among the most aggressive paediatric cancers, with overall survival rates below 30%. The genetic hallmark of MRTs is the biallelic inactivation of SMARCB1 (or, rarely, SMARCA4). This single-driver, loss-of-function alteration disrupts epigenetic regulation, leading to uncontrolled proliferation and impaired differentiation. Unlike many cancers with complex mutational landscapes, MRTs are largely epigenetically driven, which raises the possibility that restoration of SMARCB1 function could reverse malignant phenotypes.
Current treatment relies on highly toxic chemotherapy and radiotherapy regimens, which provide limited benefit and cause severe long-term side effects. No targeted therapies exist, underscoring an urgent unmet clinical need. BEAT-MRT builds on ERC-funded discoveries demonstrating that reintroduction of SMARCB1 halts proliferation and induces differentiation in MRT models, establishing a therapeutic opportunity. We will test whether CRISPR-mediated base editing can be used to correct SMARCB1 mutations in vivo, delivered through engineered virus-like particles or adeno-associated virus vectors.
Using luciferase-expressing patient-derived xenograft models, tumour progression will be monitored in real time, and efficacy will be measured as reduced tumour growth and prolonged survival. Molecular analyses will validate SMARCB1 repair and confirm safety. The main project outcome will be the demonstration that targeted genomic correction of SMARCB1 can control MRT progression in vivo. If successful, this would establish a first-in-class therapeutic approach for a devastating childhood cancer and provide a proof of principle for treating monogenic, epigenetically driven malignancies through functional gene restoration.
This PoC will also assess IP, market potential, and business strategy, laying the groundwork for translational development and follow-up funding opportunities.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Prinses Maxima Centrum Voor Kinderoncologie BV | Utrecht | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI